You can buy or sell ADAP and other stocks, options, and ETFs commission-free!
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. The listed name for ADAP is Adaptimmune Therapeutics plc American Depositary Shares.
52 Week High
52 Week Low
— per share
Expected Feb 25, Pre-Market